Abstract: A fluid distribution material for an absorbent article includes a formed film that includes a first side and a second side opposite the first side. The first side includes a plurality of elongated ridges extending from a first land area, a plurality of valleys defined by adjacent elongated ridges and the first land area, and a plurality of primary apertures located at bottoms of the valleys. The second side includes a plurality of apertured protuberances extending from a second land area. Each of the protuberances includes a continuous sidewall extending from the second land area to a distal end that includes a secondary aperture substantially aligned with a primary aperture. The formed film has a thickness greater than about 0.9 mm under a pressure of 0.071 psi, and a thickness greater than about 0.3 mm under a pressure of 0.6 psi.

Abstract: A fluid distribution material for an absorbent article includes a formed film that includes a first side and a second side opposite the first side. The first side includes a plurality of elongated ridges extending from a first land area, a plurality of valleys defined by adjacent elongated ridges and the first land area, and a plurality of primary apertures located at bottoms of the valleys. The second side includes a plurality of apertured protuberances extending from a second land area. Each of the protuberances includes a continuous sidewall extending from the second land area to a distal end that includes a secondary aperture substantially aligned with a primary aperture. The formed film has a thickness greater than about 0.9 mm under a pressure of 0.071 psi, and a thickness greater than about 0.3 mm under a pressure of 0.6 psi.

Abstract: The invention provides a measurement device and method for measuring a cyclist's power output, in response to an external force provided by said cyclist applied to a bicycle, including a force sensor (13), characterised in that said force sensor is embedded in a bicycle cleat (11) bolted to the shoe (10). The invention further provides an accelerometer (14) for measuring a cyclist's power output. The inventive device and method provides a number of advantages over prior art solutions. The device of the invention means that the installation does not need any part of the bicycle to be replaced. The present invention does not restrict the type of components that may be used on the bicycle. Because the sensors are embedded in the cleat it is very simple to move the system to another bicycle. The invention also allows for detailed analysis of pedalling style, leading to improvements in efficiency.

Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilizing substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.

Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.

Abstract: The invention provides a measurement device and method for measuring a cyclist's power output, in response to an external force provided by said cyclist applied to a bicycle, comprising a force sensor (13), characterised in that said force sensor is embedded in a bicycle cleat (11) bolted to the shoe (10). The invention further provides an accelerometer (14) for measuring a cyclist's power output. The inventive device and method provides a number of advantages over prior art solutions. The device of the invention means that the installation does not need any part of the bicycle to be replaced. The present invention does not restrict the type of components that may be used on the bicycle. Because the sensors are embedded in the cleat it is very simple to move the system to another bicycle. The invention also allows for detailed analysis of pedalling style, leading to improvements in efficiency.

Abstract: There is provided the use of monomeric TGF-?s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-?3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.

Abstract: The present invention concerns a method for folding a Transforming Growth Factor Beta, or a functional analogue thereof, into a dimeric, biologically active form. The method involves adding solubilized, unfolded monomeric growth factor to a solution containing 2-(cyclohexylamino)-ethanesulfonic acid (CHES) or a functional analogue thereof and a low molecular weight sulfhydryl/disulfide redox system. The solution is then incubated under conditions suitable for generating dimeric biologically active Transforming Growth Factor Beta.

Abstract: Provided is a method for the expression of a TGF-? in a plant. A chimeric nucleic acid sequence comprising: (1) a first nucleic acid sequence capable of regulating the transcription in a plant cell of (2) a second nucleic acid sequence, encoding a TGF-?, and adapted for expression in the plant cell; and (3) a third nucleic acid sequence encoding a termination region functional in said plant cell is introduced into a plant cell and the plant cell grown to produce TGF-?. The nucleic acid sequence may preferably be adapted for expression in a plant chloroplast. It is preferred that the TGF-? is TGF-?3, whether full length or in the form of an active fragment.

Abstract: The present invention concerns a method for folding a Transforming Growth Factor Beta, or a functional analogue thereof, into a dimeric, biologically active form. The method involves adding solubilized, unfolded monomeric growth factor to a solution containing 2-(cyclohexylamino)-ethanesulfonic acid (CHES) or a functional analogue thereof and a low molecular weight sulfhydryl/disulfide redox system. The solution is then incubated under conditions suitable for generating dimeric biologically active Transforming Growth Factor Beta.

Abstract: There is provided the use of monomeric TGF-?s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-?3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.

Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.